Donanemab: Conflicts of interest found in FDA committee that approved new Alzheimer's drug. Lenzer J, Brownlee S. BMJ 2024;386:q2010.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Lenzer J, Brownlee S. Donanemab: Conflicts of interest found in FDA committee that approved new Alzheimer's drug. BMJ 2024;386:q2010.
PMID: 39322239